GlassScriptPhysician profile
Sylvia Keiser
NPI 1366063463
$1,115.51
in general payments reported to CMS, 2019-2025
10 companies · $449 in 2025
The $449 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $296 · 2024: $371 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047 · Education: $68.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.46 |
| Education | $68.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $234.83 | 2023-2025 | Endoflip, Pillcam |
| Janssen Biotech, INC. | $187.86 | 2024-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $133.73 | 2024 | Tremfya, Remicade, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $116.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $111.82 | 2023 | Andexxa |
| Olympus America INC. | $111.79 | 2023-2025 | Disposable Emr Kit, Single Use Electrosurgical Snare Sd-400, Evis Exera III Colonovideoscope |
| Boston Scientific Corporation | $104.37 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $64.93 | 2025 | Terlivaz |
| Madrigal Pharmaceuticals | $25.27 | 2025 | Rezdiffra |
| Ardelyx, INC. | $24.20 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.